Skip to Content

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

In this MEDtalk Eric Pujade-Lauraine presents the key results of the study retreatment with maintenance olaparib in patients with ovarian cancer, previously treated with a PARP inhibitor.

Eric Pujade-Lauraine

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top